B

일동홀딩스

000230KOSPI의약품 제조업

57.3 / 100

Reference Date: 2026-06-10

Financial Score24.0 / 40
News Sentiment21.3 / 25
Momentum2.0 / 20
Disclosure10.0 / 15
AI Analysis: PER is significantly undervalued vs. peers but the high debt ratio poses financial risk. Plunged 24.2% over the past month, and news sentiment is neutral.

Company InformationBased on 2025 Annual Report

Business Overview

Iljung Holdings operates seven business divisions, including pharmaceuticals, advertising, ion water generators, software and medical devices, functional foods, and clinical pharmacology consulting. The company's main revenue comes from pharmaceutical manufacturing and sales (614.94 billion won) and software/medical device development (27.99 billion won), while advertising and ion water generator segments experienced declines compared to the previous year.

Number of Employees

84people

Average Salary

62.3M KRW

Score Calculation Basis

Detailed Financial Score

PER
3.66Industry Average 11.938.0Point

Half of industry avg (excellent)

PBR
0.23Industry Average 0.897.0Point

Half of industry avg (excellent)

ROE
7.20Industry Average 4.015.5Point

1.8x industry avg (good)

Debt Ratio
40.61Industry Average 12.430.0Point

3.3x industry avg (risky)

Trend 2023~20253.5 / 10 points
Revenue Growth Rate
0.5 / 3

Avg ▼3.6% (2-year basis)

Operating Profit Growth Rate
3.0 / 3

Avg ▲407.9% (2-year basis)

ROE Trend
0.0 / 4

Avg ROE -12.2% (improving, 3yr)

Detailed News Sentiment

1 totalPositive 1Neutral 0Negative 0Average Sentiment Score 85

Detailed Momentum

52-week position1.0Point

Near 52w low (0%, downtrend)

Current 6,840Won52-week high 15,81052-week low 6,810
1-month return0.0Point

1m -24.25% (strong drop)

Volume trend1.0Point

Volume decreasing

Detailed Disclosure

4 totalPositive 0Neutral 4Negative 0
  • Neutral기업지배구조보고서공시2026-05-29
  • Neutral주식등의대량보유상황보고서(일반)2026-05-21
  • Neutral분기보고서 (2026.03)2026-05-15
  • Neutral연결재무제표기준영업(잠정)실적(공정공시)2026-05-13